Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Ewald van den Bremer worked in antibody biology and biotechnology for more than 12 years. He holds a Ph.D. in biomolecular mass spectrometry from Utrecht University (2004) and worked at Genmab since 2006. Ewald is as an expert in analytical chemistry of biomolecules and antibodies in particular. Contributed to the research and development of the therapeutic antibodies ofatumumab (Arzerra®) and daratumumab (Darzalex®) and is an inventor of the DuoBody® technology that enables the development of bispecific antibodies. His group is mainly focused on advanced mass spectrometry-based methods for the analysis of innovative antibody therapeutics.